companies innovating in obesity treatment glp-1 drugs 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care 9 Companies Developing Next-Generation GLP-1

Oncogene-induced cellular senescence

The proportion of patients achieving NASH resolution in the absence of fibrosis progression was 40%, 36%, and 59% for the 0.1, 0.2, and 0.4 mg semaglutide arms, respectively, whereas the corresponding rate in the placebo arm was 17% (Newsome et al., 2021)

The study also found that tirzepatide reduces the risk of ventricular arrhythmia in LPS-treated mice [60]

These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-proteincoupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon

With modern lifestyles often exposed to pollution, processed foods, and stress, the bodys natural production of glutathione may not always be enough to combat these external stressors